Biogen Inc
(STU:IDP)
€
200.2
-0.2 (-0.1%)
Market Cap: 29.24 Bil
Enterprise Value: 34.65 Bil
PE Ratio: 27.19
PB Ratio: 2.07
GF Score: 68/100 Biogen Inc to Discuss Aducanumab Phase 3 Topline Results at AAN Presentation Transcript
May 18, 2020 / 08:00PM GMT
Release Date Price:
€293.75
(+1.22%)
Samantha Budd Haeberlein
Biogen Inc. - VP of Clinical Development
Presentation
May 18, 2020 / 08:00PM GMT
=====================
Corporate Participants
=====================
* Samantha Budd Haeberlein
Biogen Inc. - VP of Clinical Development
=====================
-
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot